Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal
Monday 24 February, 2025
Aachen, Germany & Toronto, Canada, 24 February 2025 – Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. (“Apotex”), the largest Canadian-based pharmaceutical company, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®…
Read More
0
